KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Sep 2025 value amounting to $1.4 million.

  • Rigel Pharmaceuticals' Gains from Investment Securities fell 7.39% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 7.39%. This contributed to the annual value of $331,000 for FY2024, which is 90.30% down from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Gains from Investment Securities of $1.4 million as of Q3 2025, which was up 0.85% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Gains from Investment Securities registered a high of $9.7 million during Q1 2021, and its lowest value of -$510,000 during Q1 2022.
  • For the 3-year period, Rigel Pharmaceuticals' Gains from Investment Securities averaged around $2.1 million, with its median value being $1.4 million (2025).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 377.27% in 2022, then spiked by 141,366.90% in 2024.
  • Over the past 5 years, Rigel Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $39,000 in 2021, then spiked by 1,669.23% to $690,000 in 2022, then crashed by 84.78% to $105,000 in 2023, then skyrocketed by 10,759.72% to $1.5 million in 2024, then dropped by 7.39% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.4 million for Q2 2025, and $605,514 during Q1 2025.